Clinical Trial

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-02-20; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Recruiting 2019-08-22
Trial Details
NCT Number NCT03850418
Lead Sponsor Henry Ford Health System
Conditions Myeloid Malignancy
Enrollment 43 participants
Start Date 2019-07-01
Primary Completion 2028-02-20 (estimated)
Study Completion 2028-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-02-24